Humasis KRX:205470KOSDAQ
휴마시스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days4
DART filings, 7 days0
Articles tracked9since Sep 11
In Q2 2026, Humasis reported revenue of ₩7.7bn, down 12.8% year on year, and an operating loss of ₩3.3bn. Humasis (휴마시스) appeared in 4 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 29 with 4 articles. The most common catalyst was risk & warnings (4). It was most often mentioned alongside Celltrion.
Filing signals 4 quarters of losses Screener
Humasis quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩7.7bn | -12.8% | −₩3.3bn margin −42.8% | −₩17.1bn |
| Q1 2026 | ₩8.9bn | +44.8% | −₩1.6bn margin −18.2% | ₩3.3bn |
| Q4 2025 derived | ₩6.4bn | -46.1% | −₩3.3bn margin −51.8% | −₩12.5bn |
| Q3 2025 | ₩8.7bn | -17.9% | −₩2.5bn margin −28.3% | −₩335m |
| Q2 2025 | ₩8.9bn | +708.4% | −₩2.0bn margin −23.1% | −₩6.0bn |
| Q1 2025 | ₩6.2bn | +229.8% | −₩2.7bn margin −44.3% | −₩3.0bn |
| Q4 2024 derived | ₩11.9bn | +288.7% | −₩2.9bn margin −24.7% | −₩33.6bn |
| Q3 2024 | ₩10.5bn | +172.0% | −₩1.1bn margin −10.5% | −₩4.7bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Humasis top stories 2 weeks, by number of outlets
- 1
- 2
- 3
Latest Humasis news Korean headlines
-
셀트리온, 공정위 6억3000만원 과징금에 행정소송 … "휴마시스 납기 지연으로 피해"
1 more on this story · 1 outlets
- 셀트리온, 공정위 6.3억 과징금에 행정소송…“휴마시스 납기 지연”한스경제 · Oct 29 13:28
-
Featured러시아 페스트 유출 우려에 휴마시스·국제약품 등 강세
1 more on this story · 1 outlets
- 러시아 페스트 유출 우려에 국제약품·녹십자엠에스 강세[Why 바이오]서울경제 · Oct 7 10:25